ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GERN Geron Corp

4.68
0.39 (9.09%)
27 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Geron Corp NASDAQ:GERN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.39 9.09% 4.68 4.65 4.68 4.77 4.35 4.35 12,882,536 00:56:18

Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023

27/07/2023 9:30pm

Business Wire


Geron (NASDAQ:GERN)
Historical Stock Chart


From Jul 2023 to Jul 2024

Click Here for more Geron Charts.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its second quarter 2023 financial results on Thursday, August 3, 2023 at 4:00 p.m. Eastern Time via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results, as well as business highlights, at 4:30 p.m. Eastern Time the same day.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL.

About Geron

Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/or follow us on LinkedIn.

Aron Feingold Investor and Media Relations investor@geron.com media@geron.com

1 Year Geron Chart

1 Year Geron Chart

1 Month Geron Chart

1 Month Geron Chart